Ftse Mib
33.986,90
1,06%
DAX
18.175,21
1,01%
S&P 500
5.180,74
1,03%
NASDAQ
16.349,25
1,19%
Bitcoin
63.687,97
0,83%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Unicycive Therapeutics Inc (UNCY) Unicycive Therapeutics Inc (UNCY) Notizie

Unicycive Therapeutics Inc

UNCY
1,1701
0,0501 (4,47%)
07 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
10/4/202413:03GLOBEUnicycive Therapeutics to Present at the Noble Capital..
28/3/202421:15GLOBEUnicycive Therapeutics Announces Full Year 2023 Financial..
25/3/202412:03GLOBEUnicycive Therapeutics to be Featured in Multiple..
14/3/202412:03GLOBEUnicycive Announces $50 Million Private Placement
13/3/202412:03GLOBEUnicycive Therapeutics Delivers Both an Oral and Poster..
07/3/202422:12GLOBEUnicycive Therapeutics Completes Enrollment in Pivotal..
04/3/202413:03GLOBEUnicycive Therapeutics Announces Orphan Drug Designation..
21/2/202422:06EDGAR2Form 8-K - Current report
14/2/202413:03GLOBEUnicycive Therapeutics to Present Two Posters on..
29/1/202413:03GLOBEUnicycive Therapeutics Announces Both an Oral and Poster..
23/1/202413:03GLOBEUnicycive Therapeutics Issues Shareholder Letter to..
22/1/202422:27EDGAR2Form SC 13G - Statement of acquisition of beneficial..
18/12/202313:03GLOBEUnicycive Therapeutics Announces Enrollment of First Patient..
08/12/202322:36EDGAR2Form S-8 - Securities to be offered to employees in employee..
29/11/202313:03GLOBEUnicycive Therapeutics to Participate in Two Investor..
14/11/202322:20EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/11/202322:15GLOBEUnicycive Announces Third Quarter 2023 Financial Results and..
23/10/202317:12EDGAR2Form 8-K - Current report
23/10/202313:03GLOBEUnicycive Therapeutics Reaches Alignment with the FDA on..
25/9/202322:05EDGAR2Form 8-K - Current report
07/9/202322:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/9/202322:05EDGAR2Form 3 - Initial statement of beneficial ownership of..
06/9/202315:16EDGAR2Form 8-K - Current report
06/9/202313:03GLOBEUnicycive Therapeutics Strengthens Board of Directors with..
31/8/202322:16EDGAR2Form 8-K - Current report
30/8/202322:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/8/202322:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/8/202322:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/8/202313:03GLOBEUnicycive Therapeutics Featured on Nasdaq Amplify Issuer..
14/8/202323:36GLOBEUnicycive Announces Second Quarter 2023 Financial Results..
14/8/202323:12EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
31/7/202322:15EDGAR2Form 8-K - Current report
26/7/202312:05EDGAR2Form 8-K - Current report
20/7/202313:03GLOBEUnicycive Therapeutics to Participate in the H.C. Wainwright..
18/7/202313:03GLOBEUnicycive Therapeutics Announces Publication of Positive..
14/7/202322:30EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14/7/202301:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/7/202301:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/7/202300:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/6/202323:04GLOBEUnicycive Therapeutics Provides Regulatory Update on..
16/6/202313:38GLOBEUnicycive to Participate in the Healthcare Virtual..
16/5/202314:29GLOBEUnicycive Announces First Quarter 2023 Financial Results and..
Apertura: 1,13 Min: 1,10 Max: 1,21
Chiusura: 1,12

La tua Cronologia

NASDAQ
UNCY
Unicycive Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network